Merck & Co.
As a leader in biopharmaceuticals, we focus on scientific innovation to deliver medicines and vaccines that may help millions of people around the world.
We’re a global health care company working to deliver innovative health solutions through our medicines, vaccines, biologic therapies and animal health products. We’re focused on discovering new solutions for today and the future.
We aspire to be the premier research-intensive biopharmaceutical company. We’re at the forefront of research to deliver innovative health solutions that advance the prevention and treatment of diseases in people and animals.
213 E Grand Ave, South San Francisco, CA
33 Avenue Louis Pasteur, Boston, MA
320 Bent St, Cambridge, MA
33 Avenue Louis Pasteur, Boston, MA
320 Bent St, Cambridge, MA
Explore Careers In
Our Therapeutic Areas:
We hold ourselves to the highest standards of ethics and integrity.
We’re driven by a desire to improve life
Our values represent the core of our character and guide every decision and action we take.
Patients first
Respect for people
Ethics and integrity
Innovation and scientific excellence
Don’t just join a company … find a sense of belonging! Our Employee Business Resource Groups (EBRGs) are voluntary, employee-led groups that aim to foster a diverse, inclusive work environment by supporting career development while providing culturally relevant insights that drive success. These groups and the people in them will provide a warm welcome to you.
Get to know us personally through employee spotlights, blogs and our podcast! Follow us on careers social for interview tips, resume tips, DEI, divisional information and more!
X | Facebook | Instagram | YouTube | Careers Blog | Career On Purpose Podcast
Blog Post
Sherif Chalifa, Business Analyst for Quality Systems
Sherif Chalifa, Business Analyst for Quality Systems
As I reflect on my time since joining Merck earlier this year, I am thrilled to say that it has been an excellent experience thus far.
Our Business
Our Business
Our Business
Make a change
Make a change
How we hire
How we hire
A decade of oncology advancements
A decade of oncology advancements
NEWS
Merck and Kelun-Biotech’s antibody-drug conjugate achieved a 22% objective response rate and 80.5% disease control rate in heavily pretreated patients with gastric or gastroesophageal junction cancer.
As the antibody-drug conjugate space continues to heat up, Merck has acquired preclinical startup Abceutics—spun out of the University at Buffalo—and its novel platform that aims to make ADC therapeutics safer.
Seeking a potential slice of the challenging KRAS market, Merck has launched a Phase III NSCLC trial of its oral G12C inhibitor MK-1084, in combination with Keytruda, in pursuit of Amgen and Bristol Myers Squibb.
Keytruda can now be used in the European Union for patients with resectable non-small cell lung cancer at high risk of recurrence in combination with platinum chemotherapy, then continued as a monotherapy afterwards.
Merck’s Winrevair is the second PAH drug to get the FDA’s green light in the past week, following Johnson & Johnson’s Opsynvi, which won approval on Friday.
Drugmakers are testing a variety of biologics and small molecules in conjunction with therapies aimed at modulating the immune system to target and destroy cancer cells.
Keytruda, when used with AstraZeneca’s Lynparza, did not significantly improve overall and progression-free survival in specific patients with metastatic non-squamous non-small cell lung cancer.
The PD-1 inhibitor Keytruda significantly improved overall survival in a late-stage trial when used with chemoradiotherapy to treat patients with newly diagnosed advanced cervical cancer.
Merck is looking to expand its offerings in the human papillomavirus space with a new vaccine and to study a single-shot variant of Gardasil 9, both of which will start trials toward the end of 2024.
JOBS
IN THE PRESS